Stock AnalizNovartis AG NVS
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Novartis AG (NVS) is a healthcare company listed in the US with a market value of about $306.3B. In the twelve months to September 30, 2026 it had revenue of $57.4B and net income of $10.0B, a net margin of 17.5%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is track record (4/5); the weakest is value (0/5).
Key numbers: a P/E of 30.7, a price to free cash flow of 21.9, 5-year revenue growth of 2% a year, a 5-year average ROIC of 14%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 9% below the current price.
Score: 2.0 / 5
Checks passed
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- ROE above 15%
- Positive free cash flow
- Interest covered more than 5 times
- Liabilities below 60% of assets
- Pays a dividend
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $57.4B | $54.5B | $50.3B | $45.4B | $42.2B | $42.8B | $48.7B | $47.5B | $44.8B | $42.4B | $48.5B |
| Net income | $10.0B | $14.0B | $11.9B | $14.8B | $7.0B | $24.0B | $8.1B | $11.7B | $12.6B | $7.7B | $6.7B |
| Free cash flow | $14.0B | $17.6B | $16.3B | $13.4B | $13.3B | $14.0B | $12.4B | $12.2B | $13.0B | $11.3B | $9.6B |
| EPS (diluted) | $5.23 | $7.33 | $6.26 | $7.78 | $3.64 | $12.59 | $4.23 | $6.15 | $6.61 | $4.04 | $3.52 |
| Net margin | 17.5% | 25.6% | 23.7% | 32.7% | 16.5% | 56.1% | 16.6% | 24.7% | 28.1% | 18.2% | 13.8% |
| ROIC | — | 20.1% | 18.5% | 13.6% | 8.2% | 10.1% | 9.7% | 9.3% | 7.3% | 7.3% | 9.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $157.10, 2% below the current price; targets range from $130.00 to $185.00; the consensus rating is “Hold”; expected EPS is $9.07 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Novartis’s P/E ratio?
About 30.7, based on the last twelve months of diluted earnings per share (forward P/E about 17.0).
Is Novartis stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 9% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Novartis pay a dividend?
Yes. The dividend yield is about 2.95%, and it has paid dividends for 10 years in our data.
Is Novartis a good stock to buy?
We do not give buy or sell advice. Novartis scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.